Zelgen(SH:688266) Xin Lang Zheng Quan·2025-06-06 05:38Core Insights - The 2025 ASCO Annual Meeting will take place from May 30 to June 3 in Chicago, showcasing high-quality research results from domestic innovative drug products [1] - Several innovative drug molecules with first-in-class or best-in-class potential will present data, including IBI363, SKB264, BL-B01D1, 707, ZL-1301, HLX43, and DB-1311 [1] - Zai Lab's PD-1/TIGIT bispecific antibody ZG005 has two clinical studies selected for oral presentation, focusing on its efficacy in treating advanced cervical cancer [1] Clinical Trials Overview - The ZG005-001 study is a first-in-human Phase I trial with 55 advanced cervical cancer patients enrolled, showing an overall response rate (ORR) of 40.9% and a disease control rate (DCR) of 68.2% in the 20 mg/kg group [2] - The ZG005-003 study is a multicenter, open-label Phase I/II trial, with 41 patients enrolled so far, showing an ORR of 69.2% for the 10 mg/kg group and 80.0% for the 20 mg/kg group among evaluable patients [3] Treatment Context - Cervical cancer is a common gynecological malignancy, with standard first-line treatment involving platinum-based chemotherapy combined with bevacizumab [3] - ZG005's efficacy data in combination with chemotherapy and bevacizumab is slightly lower than that of the comparator drug, but it shows superior efficacy in second-line treatment and a lower incidence of grade 3 or higher adverse reactions [3][4]